[Retinal vein occlusion : Epidemiology, classification and clinical findings].

Abstract

Since the introduction of intravitreal operative medication injections (IVOM), the therapy of retinal vein occlusion (RVO) has permanently changed. The growing acceptance of IVOM is undoubtedly due to the generally positive outcome after RVO. During the pharmaceutical trials required to obtain medication approval, extensive data were collected on the spontaneous course of the disease and the risk factors responsible for the disease. As RVO is a complication of systemic or local risk factors, these data are also useful for the therapy of the underlying risk factors. In this article the currently available data are presented and evaluated to provide the reader with key guidelines to diagnose and treat this complex syndrome.

• Authors: N Feltgen, A Pielen
• Journal: Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft (Ophthalmologe) Vol. 112 Issue 7 Pg. 607-18; quiz 619-20 (Jul 2015) ISSN: 1433-0423 [Electronic] Germany
• Vernacular Title: Retinaler Venenverschluss : Epidemiologie, Einteilung und klinische Befunde.
• PMID: 26162973 (Publication Type: Journal Article, Review)

Chemical References

• Angiogenesis Inhibitors

Topics

• Angiogenesis Inhibitors (administration & dosage)
• Combined Modality Therapy (methods)
• Evidence-Based Medicine
• Humans
• Light Coagulation (methods)
• Prevalence
• Retinal Vein Occlusion (diagnosis, epidemiology, therapy)
• Risk Factors
• Treatment Outcome